Vaginal natural oxygenation device holds promise in treatment of vulvovaginal atrophy
The vaginal natural oxygenation device (VNOD) appears to provide a completely natural type of therapy for vulvovaginal atrophy (VVA) that is well accepted by patients, inducing immediate therapeutic effects without side effects, according to the results of a pilot study.
VNOD concomitantly administers hyaluronic acid and topical hyperbaric oxygen therapy (THOT) through a cannula specifically designed for vaginal therapy. The device is composed of a compressor unit and a base unit, which is equipped with an on-board computer and a graphic-touchscreen interface that allows flow modulation.
In the current trial, 25 patients with severe VVA (mean age at diagnosis 56.6 years) received five biweekly treatment sessions. During each session, VNOD delivered 95 percent pure oxygen at a flow of 2 L/min for 15 minutes and a solution of low molecular weight sodium hyaluronate at 0.2 percent in the last 5 minutes.
At the last therapy session, the intensity of symptoms—measured using a graduated scale of 1–6, with 1 indicating maximum intensity and 6 indicating absence of symptom—significantly decreased from baseline. [Eur Rev Med Pharmacol Sci 2018;22:8480-8486]
Specifically, average scores for well-being such as absence of dyspareunia improved from 0.3 to 5.1, vaginal burning from 0.2 to 5.1, presence of fluid from 0.6 to 4.9, vaginal epithelium appearance from 1.8 to 4.7, and vaginal elasticity from 1.1 to 3.8 (p<0.001 for all).
Finally, all patients reported recovery of their sexuality at the end of the five treatment sessions.
The present data demonstrate very high efficacy of the VNOD for VVA, reducing burning symptoms and increasing elasticity of the vaginal epithelium even after just the first session, researchers noted.
Analyses of the comparisons between the different phases of therapy have shown that each subsequent session produced a significant increase in all parameters, except for vaginal elasticity and vaginal epithelium appearance during the last treatment interval (sessions four to five), researchers noted. This suggests that four sessions are sufficient to achieve the maximum result with VNOD for vaginal elasticity and epithelium appearance.
Further studies are needed to validate the effectiveness of combined THOT and hyaluronic acid therapy via VNOD, as well as to confirm the reported beneficial effects on urinary symptoms such as dysuria, pollakiuria and mild incontinence, they said.